Mechanism and function of monoclonal antibodies targeting Siglec-15 for therapeutic inhibition of osteoclastic bone resorption

Journal of Biological Chemistry

Volumn 289, Issue 10, 2014, Pages 6498-6512

  Stuible, Matthew ^a   Moraitis, Anna ^a   Fortin, Annie ^a   Saragosa, Stefan ^a   Kalbakji, Aida ^a   Filion, Mario ^a   Tremblay, Gilles B ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANES; DISEASES; MOLECULAR BIOLOGY; MONOCLONAL ANTIBODIES;

BONE LOSS; BONE RESORPTION; IN-VIVO; MECHANISM OF ACTION; OSTEOCLAST DIFFERENTIATION; RECEPTOR ENDOCYTOSIS;

BONE;

KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 15; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CELL ACTIVITY; CELL COUNT; CELL DIFFERENTIATION; CELL MEMBRANE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; ENDOCYTOSIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; INTRACELLULAR SIGNALING; LYSOSOME; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

ANTI-RESORPTIVE; ANTIBODIES; BONE; CELL SIGNALING; OSTEOCLAST; RECEPTOR ENDOCYTOSIS; SIGLEC-15;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CELL LINE; HUMANS; IMMUNOGLOBULINS; MEMBRANE PROTEINS; MICE; OSTEOCLASTS; RANK LIGAND;

EID: 84896765143     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.494542     Document Type: Article

References (40)

1. Boyle, W. J., Simonet, W. S., and Lacey, D. L. (2003) Osteoclast differentiation and activation. Nature 423, 337-342
2. Liu, Q. Y., Sooknanan, R. R., Malek, L. T., Ribecco-Lutkiewicz, M., Lei, J. X., Shen, H., Lach, B., Walker, P. R., Martin, J., and Sikorska, M. (2006) Novel subtractive transcription-based amplification of mRNA (STAR) method and its application in search of rare and differentially expressed genes in AD brains. BMC Genomics 7, 286
3. Sooknanan, R. R., Tremblay, G. B., and Filion, M. (August 2, 2011) Polynucleotides and polypeptide sequences involved in the process of bone remodeling. Alethia Biotherapetuics, United States Patent 7,989,160
4. O'Reilly, M. K., and Paulson, J. C. (2009) Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol. Sci. 30, 240-248
5. Hiruma, Y., Hirai, T., and Tsuda, E. (2011) Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation. Biochem. Biophys. Res. Commun. 409, 424-429
6. Ishida-Kitagawa, N., Tanaka, K., Bao, X., Kimura, T., Miura, T., Kitaoka, Y., Hayashi, K., Sato, M., Maruoka, M., Ogawa, T., Miyoshi, J., and Takeya, T. (2012) Siglec-15 regulates the formation of functional osteoclasts in concert with DNAX-activating protein of 12 kDa (DAP12). J. Biol. Chem. 287, 17493-17502
7. Crocker, P. R., Paulson, J. C., and Varki, A. (2007) Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7, 255-266
8. Law, C. L., Sidorenko, S. P., Chandran, K. A., Zhao, Z., Shen, S. H., Fischer, E. H., and Clark, E. A. (1996) CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C(1) upon B cell activation. J. Exp. Med. 183, 547-560
9. Taylor, V. C., Buckley, C. D., Douglas, M., Cody, A. J., Simmons, D. L., and Freeman, S. D. (1999) The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J. Biol. Chem. 274, 11505-11512
10. Angata, T., Hayakawa, T., Yamanaka, M., Varki, A., and Nakamura, M. (2006) Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates. FASEB J. 20, 1964-1973
11. Blasius, A. L., Cella, M., Maldonado, J., Takai, T., and Colonna, M. (2006) Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood 107, 2474-2476
12. Turnbull, I. R., and Colonna, M. (2007) Activating and inhibitory functions of DAP12. Nat. Rev. Immunol. 7, 155-161
13. Lanier, L. L. (2009) DAP10-and DAP12-associated receptors in innate immunity. Immunol. Rev. 227, 150-160
14. Angata, T., Tabuchi, Y., Nakamura, K., and Nakamura, M. (2007) Siglec-An immune system Siglec conserved throughout vertebrate evolution. Glycobiology 17, 838-846
15. Walker, J. A., and Smith, K. G. (2008) CD22. An inhibitory enigma. Immunology 123, 314-325
16. Crocker, P. R., and Redelinghuys, P. (2008) Siglecs as positive and negative regulators of the immune system. Biochem. Soc. Trans. 36, 1467-1471
17. Blasius, A. L., and Colonna, M. (2006) Sampling and signaling in plasmacytoid dendritic cells. The potential roles of Siglec-H. Trends Immunol. 27, 255-260
18. Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., and Fleisch, H. (1991) BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6, 1003-1011
19. Egan, K. P., Brennan, T. A., and Pignolo, R. J. (2012) Bone histomorphometry using free and commonly available software. Histopathology 61, 1168-1173
20. Dempster, D. W., Compston, J. E., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., Recker, R. R., and Parfitt, A. M. (2013) Standardized nomenclature, symbols, and units for bone histomorphometry. A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 28, 2-17
21. Kim, K., Lee, S. H., Ha Kim, J., Choi, Y., and Kim, N. (2008) NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol. Endocrinol. 22, 176-185
22. McHugh, K. P., Hodivala-Dilke, K., Zheng, M. H., Namba, N., Lam, J., Novack, D., Feng, X., Ross, F. P., Hynes, R. O., and Teitelbaum, S. L. (2000) Mice lacking 3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 105, 433-440
23. Humphrey, M. B., Daws, M. R., Spusta, S. C., Niemi, E. C., Torchia, J. A., Lanier, L. L., Seaman, W. E., and Nakamura, M. C. (2006) TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J. Bone Miner. Res. 21, 237-245
24. Underhill, D. M., and Goodridge, H. S. (2007) The many faces of ITAMs. Trends Immunol. 28, 66-73
25. Bonifacino, J. S., and Traub, L. M. (2003) Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu. Rev. Biochem. 72, 395-447
26. Toyomura, T., Murata, Y., Yamamoto, A., Oka, T., Sun-Wada, G. H., Wada, Y., and Futai, M. (2003) From lysosomes to the plasma membrane. Localization of vacuolar-type HATPase with the a3 isoform during osteoclast differentiation. J. Biol. Chem. 278, 22023-22030
27. Hiruma, Y., Tsuda, E., Maeda, N., Okada, A., Kabasawa, N., Miyamoto, M., Hattori, H., and Fukuda, C. (2013) Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice. Bone 53, 87-93
28. Kameda, Y., Takahata, M., Komatsu, M., Mikuni, S., Hatakeyama, S., Shimizu, T., Angata, T., Kinjo, M., Minami, A., and Iwasaki, N. (2013) Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling adaptor DAP12. J. Bone Miner. Res. 28, 2463-2475
29. Karsdal, M. A., Martin, T. J., Bollerslev, J., Christiansen, C., and Henriksen, K. (2007) Are nonresorbing osteoclasts sources of bone anabolic activity? J. Bone Miner. Res. 22, 487-494
30. Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B., Phillips, J. H., Pekkarinen, P., Lanier, L. L., Timonen, T., and Peltonen, L. (2000) Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat. Genet. 25, 357-361
31. Kaifu, T., Nakahara, J., Inui, M., Mishima, K., Momiyama, T., Kaji, M., Sugahara, A., Koito, H., Ujike-Asai, A., Nakamura, A., Kanazawa, K., Tan-Takeuchi, K., Iwasaki, K., Yokoyama, W. M., Kudo, A., Fujiwara, M., Asou, H., and Takai, T. (2003) Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J. Clin. Invest. 111, 323-332
32. Tomasello, E., and Vivier, E. (2005) KARAP/DAP12/TYROBP. Three names and a multiplicity of biological functions. Eur. J. Immunol. 35, 1670-1677
33. Mao, D., Epple, H., Uthgenannt, B., Novack, D. V., and Faccio, R. (2006) PLC2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J. Clin. Invest. 116, 2869-2879
34. Takahata, M., Iwasaki, N., Nakagawa, H., Abe, Y., Watanabe, T., Ito, M., Majima, T., and Minami, A. (2007) Sialylation of cell surface glycoconjugates is essential for osteoclastogenesis. Bone 41, 77-86
35. Raggatt, L. J., and Partridge, N. C. (2010) Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285, 25103-25108
36. Walsh, M. C., and Choi, Y. (2003) Biology of the TRANCE axis. Cytokine Growth Factor Rev. 14, 251-263
37. Roelofs, A. J., Thompson, K., Gordon, S., and Rogers, M. J. (2006) Molecular mechanisms of action of bisphosphonates. Current status. Clin. Cancer Res. 12, 6222s-6230s
38. Baron, R., Ferrari, S., and Russell, R. G. (2011) Denosumab and bisphosphonates. Different mechanisms of action and effects. Bone 48, 677-692
39. Reid, I. R., and Cornish, J. (2012) Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat. Rev. Rheumatol. 8, 90-96
40. Park-Wyllie, L. Y., Mamdani, M. M., Juurlink, D. N., Hawker, G. A., Gunraj, N., Austin, P. C., Whelan, D. B., Weiler, P. J., and Laupacis, A. (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305, 783-789